# Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma

> **NCT03654833** · PHASE2 · UNKNOWN · sponsor: **University of Leicester** · enrollment: 186 (actual)

## Conditions studied

- Mesothelioma, Malignant

## Interventions

- **DRUG:** Rucaparib
- **DRUG:** Abemaciclib
- **DRUG:** pembrolizumab & bemcentinib
- **DRUG:** Atezolizumab & Bevacizumab
- **DRUG:** Dostarlimab and Niraparib

## Key facts

- **NCT ID:** NCT03654833
- **Lead sponsor:** University of Leicester
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-28
- **Primary completion:** 2023-10-31
- **Final completion:** 2023-10-31
- **Target enrollment:** 186 (ACTUAL)
- **Last updated:** 2023-03-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03654833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03654833, "Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03654833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*